Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-27
2005-09-27
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S535000, C514S564000, C514S567000, C514S657000, C548S253000, C548S254000, C560S043000, C562S454000, C562S457000, C564S428000
Reexamination Certificate
active
06949575
ABSTRACT:
The present invention provides compounds of Formula (I) and a method of treating Alzheimer's disease using a compound of Formula (I), wherein: R1and R2include alkyl and phenylalkyl; R3is hydrogen or alkyl; and R4and R5include alkyl, alkoxy, carboxyl, alkoxycarbonyl, and nitro. Also provided is a method of inhibiting the aggregation of amyloid proteins using a compound of Formula (I)and a method of imaging amyloid deposits using compounds of Formula (I).
REFERENCES:
patent: 4816456 (1989-03-01), Summers
patent: 5006561 (1991-04-01), Arrowsmith et al.
patent: 5523314 (1996-06-01), Bue-Valleskey et al.
patent: 5658904 (1997-08-01), Ono et al.
patent: 5716975 (1998-02-01), Bue-Valleskey et al.
patent: 6001331 (1999-12-01), Caprathe et al.
patent: 2335560 (1999-01-01), None
patent: 0535496 (1992-09-01), None
patent: 0538134 (1992-10-01), None
Nakagawa et al, “Caspase-12 mediates endoplasmic reticulum-specific apoptosis and cytotoxicity by amyloid-beta” Nature, vo 403, pp. 98-103 (Jan. 6, 2000).
Thal, “Trials to slow progression and prevent disease onset” J. Neural Transm. [Suppl] vol. 59, pp. 243-249 (2000).
Reichman, W. E., “Alzheimer's Disease: Clinical Treatment Options” vol. 6(22) Sup., pp. S1125-S1138 (Dec. 2000).
Schenk et al, “Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse” Nature, vol. 400, pp. 173-177 (Jul. 8, 1999).
Lue et al, “Soluble Amyloid beta Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease” American Journal of Pathology, vol. 155(3), pp. 853-.
Mclean et al, “Soluble Pool of A-beta Amyloid as a Determinant of Severity of Neurodegeneration in Alzheimer's Disease” Annals of Neurology, vol. 46(6), pp. 860-866 (Dec. 1999).
Yan et al, “Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity” Nature, vol. 402, pp. 533 537 (Dec. 2, 1999).
Bort et al, “Comparative metabolism of the nonsteroidal antiiinflammatory drug aceclofenac, in the rat, monkey and human.” Drug metabolism and disposition: biological fate of chemicals, vol. 24(9), pp. 969-975 (1996).
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Thal, L.J. “Trials to slow progression and prevent disease onset” J. Neural Transmission, Supplementum, vol. 59, pp. 243-249 (2000).
Reichman, W.E. “Alzheimer's Disease: Clinical Treatment Options” Am. J. Managed Care, vol. 6, pp. S1133-S1138 (Dec. 2000).
Klein, William, “A.beta. toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets” Neurochemistry International, vol. 41, pp. 345-352 (2002).
Reichman, W. E. “Current pharmacologic options for patients with Alzheimer's disease” Annals of General Hospital Psychiatry, vol. 2:1, online article, 14 pages (Jan. 2003).
PCT International Search Report PCT/US01/13254.
Barta Nancy Sue
Bigge Christopher Franklin
Jubinsky J. A.
Ling L. B.
Pfizer Inc.
Richardson P. C.
Tucker Zachary C.
LandOfFree
Method of inhibiting amyloid protein aggregation and imaging... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting amyloid protein aggregation and imaging..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting amyloid protein aggregation and imaging... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435524